United Therapeutics Corp ( UTHR ) reported second-quarter financial results before the market open on Wednesday. Here’s a rundown of the report.

Q2 Revenue: $798.6 million, versus estimates of $805.48 million

Q2 EPS: $6.41, versus estimates of $7.14

Total revenue was up 12% on a year-over-year basis. Tyvaso DPI revenue was up 22% year-over-year to $315 million. Nebulized Tyvaso, Orenitram and Unituxin all showed double-digit revenue growth on a year-over-year basis.

United Therapeutics ( UTHR ) ended the quarter with approximately $4.97 billion in cash, cash equivalents and marketable securities.

“Our second quarter yet again produced record-setting results driven by the strength of our foundational commercial business,” said Martine Rothblatt, chairperson and CEO of United Therapeutics ( UTHR ).

“We continue to believe there is no other biotech company like ours that provides this combination of sales growth and operating cash flow with near- to medium-term catalysts positioned for sustained long-term growth.”

United Therapeutics ( UTHR ) said it expects data from its TETON 2 study of nebulized treprostinil in idiopathic pulmonary fibrosis in September.

UTHR Price Action: United Therapeutics ( UTHR ) shares were down 2.63% at $289.73 at the time of publication Wednesday, according to Benzinga Pro.

Read Next:

UnitedHealth Prognosis Mixed: Analysts Trim Targets But Keep Faith After Q2 Miss